

CHEMOTHERAPY

Volume 7
Cancer Chemotherapy I

CHEMOTHERAPY

- Volume 1 Clinical Aspects of Infections**
Prophylaxis; life-threatening infections; infection in leukaemia; surgical infection; anaerobic infection; respiratory and urinary tract infections; amikacin.
- Volume 2 Laboratory Aspects of Infections**
Sensitivity testing; assay methods; animal models of infection; sisomycin; tobramycin.
- Volume 3 Special Problems in Chemotherapy**
Tuberculosis; genital tract infections; antibiotic resistance and mode of action; topical chemotherapy and antisepsis.
- Volume 4 Pharmacology of Antibiotics**
Tissue concentrations; pharmacokinetics; untoward effects of antibiotics.
- Volume 5 Penicillins and Cephalosporins**
Penicillins and cephalosporins; betalactamases; new agents.
- Volume 6 Parasites, Fungi, and Viruses**
Parasitic infections; fungal infections; chemotherapy of viruses; co-trimoxazole.
- Volume 7 Cancer Chemotherapy I**
Symposia – new drugs and approaches; cell and pharmacokinetics; potentiators of radiotherapy; in vitro screening systems; immunological aspects.
- Volume 8 Cancer Chemotherapy II**
Free papers – new drugs and approaches; cell and pharmacokinetics; mechanisms of action; new analogues; cancer chemotherapy of specific organs.

CHEMOTHERAPY

Volume 7 Cancer Chemotherapy I

Edited by
K. Hellmann
*Westminster Hospital
and Imperial Cancer Research Fund*

and
T. A. Connors
Chester Beatty Research Institute

Plenum Press · New York and London

Library of Congress Cataloging in Publication Data

International Congress of Chemotherapy, 9th, London, 1975.

Cancer chemotherapy I-

(Chemotherapy; v. 7-)

1. Cancer—Chemotherapy—Congresses. I. Hellmann, Kurt. II. Connors, T. A., 1934- III. Title. IV. Series.

RM260.2.C45 vol. 7, etc. [RC271.C5] 615'58s [616.9'94'061] 76-1944

ISBN-13: 978-1-4613-4351-6

e-ISBN-13: 978-1-4613-4349-3

DOI: 10.1007/ 978-1-4613-4349-3

Proceedings of the Ninth International Congress of Chemotherapy
held in London, July, 1975 will be published in eight volumes,
of which this is volume seven.

© 1976 Plenum Press, New York

Softcover reprint of the hardcover 1st edition 1976

A Division of Plenum Publishing Corporation
227 West 17th Street, New York, N. Y. 10011

United Kingdom edition published by Plenum Press, London
A Division of Plenum Publishing Company, Ltd.
Davis House (4th Floor), 8 Scrubs Lane, Harlesden, London, NW10 6SE, England

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted,
in any form or by any means, electronic, mechanical, photocopying, microfilming,
recording, or otherwise, without written permission from the Publisher

CHEMOTHERAPY

Proceedings of the
9th International Congress of Chemotherapy
held in London, July, 1975

Editorial Committee

K. Hellmann, *Chairman* (Anticancer)
Imperial Cancer Research Fund, London.

A. M. Geddes (Antimicrobial)
East Birmingham Hospital.

J. D. Williams (Antimicrobial)
The London Hospital Medical College.

Congress Organising Committee

W. Brumfitt	I. Phillips	H.P. Lambert
K. Hellmann	M.R.W. Brown	P. Turner
K.D. Bagshawe	D.G. James	A.M. Geddes
H. Smith	C. Stuart-Harris	D. Armitage
E.J. Stokes	R.G. Jacomb	D. Crowther
F. Wrigley	D.T.D. Hughes	D.S. Reeves
J.D. Williams	T. Connors	R.E.O. Williams

International Society of Chemotherapy Executive - to July 1975

P. Malek	H.P. Kuemmerle	H. Ericsson
C. Grassi	Z. Modr	G.M. Savage
G.H. Werner	K.H. Spitzy	H. Umezawa
	P. Rentchnick	

Preface

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, penicillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, especially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tuberculosis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods.

From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of current progress in chemotherapy.

We thank the authors of these communications for their cooperation in enabling the Proceedings to be available at the earliest possible date. The method of preparation does not allow for uniformity of typefaces and presentation of the material and we hope that the blemishes of language and typographical errors do not detract from the understanding of the reader and the importance of the Proceedings.

K. HELLMANN, Imperial Cancer Research Fund
A. M. GEDDES, East Birmingham Hospital
J. D. WILLIAMS, The London Hospital Medical College

Contents

Advances in Cancer Chemotherapy	1
E. Frei III	
Experimental Basis of Cancer Chemotherapy	19
N. Brock	
New Leads Towards Antitumor Selectivity in Therapeutics . . .	51
E. Mihich	
An Experimental Approach to Increase Selective Tumour Toxicity of Methotrexate	57
M. H. N. Tattersall	
Alterations in Intracellular Cyclic AMP as a Potential Form of Antitumour Chemotherapy	69
M. J. Tisdale and B. J. Phillips	
The Drug-Carrier Potential of Liposomes in Cancer Chemotherapy	75
G. Gregoriadis	
Significance of Prostaglandins in Tumour Growth	83
J. A. C. Sykes	
Oestrogen Binding as a Predictive Test for DMBA- Induced Tumour Response to Tamoxifen Therapy	89
V. C. Jordan and T. Jaspan	
Action of Anticancer Drugs on the Cell Cycle. Chromosome Damage and Differential Stage Sensitivity	95
D. Scott	
Adriamycin Metabolism in Man	105
N. R. Bachur	

Pharmacokinetics of Anticancer Drugs	113
W. Sadée	
Pharmacokinetics and Metabolism of Anticancer Drugs	119
T. L. Loo	
The Activity of New Drugs Against Mouse Tumours	129
J. M. Venditti and M. K. Wolpert-DeFilippes	
Platinum Complexes as Anticancer Drugs	149
M. J. Cleare	
Streptozotocin, Chlorozotocin, and Related Nitrosourea Antitumour Agents	159
P. S. Schein, T. Anderson, M. G. McMenamin, and J. Bull	
Analogues and Metabolites of Cyclophosphamide	167
K. Norpoth	
ICRF 159 and Other Bisdioxopiperazines	183
K. Hellmann	
Biological Basis of Radiosensitization by Hypoxic-Cell Radiosensitizers	187
G. E. Adams, J. Denekamp, and J. F. Fowler	
Bleomycin and Radiotherapy	207
J. Rygard and H. S. Hansen	
Experience with ICRF 159 and Radiotherapy in Combination in the Treatment of Soft Tissue Sarcomas	211
R. D. H. Ryall	
Metronidazole (Flagyl) in Cancer Radiotherapy	215
J. L. Foster and R. L. Willson	
Possibilities of the Human Tumour/Nude Mouse System in Cancer Chemotherapy Research	223
C. O. Povlsen	
Chemotherapy of Transplantable Colon Tumours in Mice	225
J. A. Double	
Utilization of Nitrosamine-Induced Tumours as Models for Cancer Chemotherapy	233
D. Schmähel	

The Production of Osteolytic Substances by Human Breast Tumours	239
G. C. Easty, T. J. Powles, M. Dowsett, D. M. Easty, and A. M. Neville	
The Biological Basis of Combination Chemotherapy	243
A. Goldin	
Combination Chemotherapy of Advanced Gastrointestinal Carcinoma	249
A. J. Schutt and C. G. Moertel	
Combination Chemotherapy in Breast and Lung Cancer	255
C. G. Schmidt	
Chemotherapy of CNS Tumors	271
M. D. Walker	
Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors	277
V. A. Levin and C. B. Wilson	
Effect of CCNU on Survival, Objective Remissions, and Free Interval in Patients with Malignant Gliomas	285
EORTC Brain Tumor Group, Presented by L. Calliauw	
Intracavitary Glioma Chemotherapy	289
J. Garfield	
Screening on Enzyme Inhibitors with Potential Antitumour Activity	295
H. Umezawa	
Recent Experience with Microbial Systems and Cancer Cells In Vitro in the Screening for Antitumor Antibiotics	299
G. F. Gause	
Problems Related to the Detection of Activity of Antitumour Antibiotics	303
L. J. Hanka, D. G. Martin, P. F. Wiley, and G. L. Neil	
Attempts to Overcome Methotrexate Resistance: The Value of Drug Resistant Cell Lines	309
B. T. Hill, L. A. Price, and J. H. Goldie	
In Vitro Mutagenesis by Anti-Cancer Drugs	315
M. Fox	

In Vitro Systems Using Micro-Organisms for Detection of Carcinogenic Agents	323
R. C. Garner	
In Vitro Screening of Cytotoxic Substances Using Different Tumour Cells	327
J. Fuska, P. Vesely, L. Ivanickaja, and A. Fuskova	
In Vitro Methods for Use in Drug Metabolism Studies	335
B. J. Phillips and P. J. Cox	
Some Problems in the Use of Short Term Cultures of Human Tumours for In Vitro Screening of Cytotoxic Drugs	341
P. P. Dendy	
Combination of <u>Corynebacterium parvum</u> and Cytostatic Drugs in Disseminated Human Cancers	351
L. Israel and A. Depierre	
Radiotherapy and Chemotherapy in Acute Leukaemia Related to Fatal Infection During Remission	355
I. C. M. MacLennan	
The Target Cell of Immunosuppressive Agents	359
J. F. Bach	
Immunological Aspects of Anticancer Drugs	361
D. A. L. Davies	
List of Contributors	363